Ranibizumab injection for corneal neovascularization refractory to bevacizumab treatment.
Ranibizumab injection for corneal neovascularization refractory to bevacizumab treatment.
复制标题
DOI：
10.3341/kjo.2014.28.2.177
复制
发表时间：
2014-04
影响因子：
--
通讯作者：
Chung SK
中科院分区：
文献类型：
--
作者：
Ahn YJ;Hwang HB;Chung SK
血管内皮生长因子抑制剂是治疗各种眼部新生血管疾病的一种新的治疗方法。然而，对于角膜NV，关于贝伐单抗和雷尼比单抗哪一个更好仍存在争议。1例32岁女性患者，经结膜下和基质内两次贝伐单抗注射，确诊为疱疹病毒性角结膜炎合并难治性角膜新生血管，接受了两次结膜下和基质内雷尼比单抗注射。术后6个月，新生血管面积和血管管径明显缩小。在这里，作者报告了一个通过结膜下和基质内注射雷尼比单抗改善角膜NV的病例，这在以前是贝伐单抗注射无效的。这一发现可能为治疗角膜新生血管提供了新的前景。
Vascular endothelial growth factor inhibitor is an emerging therapeutic modality for various ocular diseases with neovascularization (NV). However, for corneal NV, controversy remains regarding whether bevacizumab or ranibizumab is superior. A 32-year-old female diagnosed with herpetic keratoconjunctivitis with refractory corneal NV despite two previous subconjunctival and intrastromal bevacizumab injections, received two subconjunctival and intrastromal ranibizumab injections. Six months postoperatively, there was significant regression of the neovascular area and vessel caliber. Here, the authors report a case of improvement in corneal NV with subconjunctival and intrastromal ranibizumab injections, which was previously refractory to bevacizumab injection. The findings may suggest a new prospect in treating corneal NV.